Hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1)

Hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) is a critical enzyme responsible for catalyzing the salvage of purine bases, hypoxanthine and guanine, to their respective nucleotides (inosine monophosphate and guanosine monophosphate), a process central to the purine salvage pathway. Its activity is necessary for recycling purines, thereby maintaining adequate nucleotide pools for DNA and RNA synthesis in virtually all cells. HPRT1 deficiency leads to rare but severe inherited disorders, including Lesch-Nyhan syndrome and HPRT-related gout, characterized by neurological dysfunction, hyperuricemia, and renal complications. Beyond inherited disease, HPRT1 is upregulated or mutated in multiple cancer types, making it relevant for both research and potential therapeutic intervention. The enzyme is also a key selection marker in cell engineering technologies, such as monoclonal antibody-producing hybridomas. Due to its central metabolic function, modulation of HPRT1 carries significant safety risks, particularly relating to uric acid handling and neurological effects.

Other names

HGPRTHGPRTaseHPRTHPRT_HUMANHypoxanthine-Guanine PhosphoribosyltransferaseGuanine PhosphoribosyltransferaseIMP PyrophosphorylaseHOX5.4

Inhibition of purine salvage pathway: inhibition increases levels of unmetabolized purines and uric acid. Drugs modulate purine metabolism and nucleotide pool availability, sometimes used to model or treat hyperuricemic conditions and aid in cell selection. Experimental targeting in cancer involves modulating expression or siRNA-induced gene silencing which affects cell proliferation, survival, and metastatic potential.